Index

absorbance 90, 143, 183, 355, 381, 427, 482, 662, 704, 761–62, 793, 845–46, 868, 895, 932
acetone 32, 163–64, 217, 351–52, 355, 398, 449, 452, 788–89, 846, 869, 953–54, 961
active targeted nanoparticles (ATN) 788, 796
ADME see adsorption, distribution, metabolism, and excretion
adsorption, distribution, metabolism, and excretion (ADME) 4, 15, 82, 84–85, 96, 140, 341, 595, 597, 625, 841, 888, 941
AFM *see* atomic force microscopy
anticancer drugs 23–28, 49–50, 70, 106–10, 125–28, 195–96, 245–46, 258–60, 345–46, 371–73, 444–45, 596–97, 675–77, 715–16, 735–37
  delivery of 362, 903, 951
  hydrophobic 31, 49, 110, 498, 953
  oral bioavailability of 171, 196, 246, 448, 498, 683, 890, 940
  oral delivery of 17, 101, 109–10, 128, 135, 154, 177, 193, 212, 229, 243, 445, 591, 715–16, 730
  targeted delivery of 26, 109, 130, 391, 498, 587
area under the curve (AUC) 10–11, 25, 44, 50, 92–93, 130, 144, 148–51, 158, 162, 170, 175, 183, 190–91, 235, 239–42, 613–17, 624, 638, 640, 642, 656, 673, 686, 690, 692–93, 700, 941–43, 947
ATN *see* active targeted nanoparticles
atomic force microscopy (AFM) 35–36, 86, 112–13, 267, 281–82, 288, 293–94, 303, 309–11, 318, 320–25, 683–84, 737–38, 890, 892
AUC *see* area-under-the curve

BBB *see* blood–brain barrier
BCEC *see* brain capillary endothelial cells
Biodegradable Copolymer Blend 358, 364, 395–96, 398, 400, 402, 404, 406, 408, 410, 412, 414, 521–22, 524, 526
biodegradable PLA-TPGS copolymers in drug delivery 951, 953, 955, 957, 959, 961, 963, 965
biodegradable polymeric nanoparticles 130
biodistribution 13, 55, 130, 159, 161–62, 164, 170, 172, 175, 342, 347, 469–71, 476, 598, 604, 614, 616–17, 623–25, 629, 638, 640, 642, 694, 704, 757, 763, 770, 777–78, 788, 791, 798–99, 803, 826, 839, 843, 880, 942, 955, 957, 960, 968
blood–brain barrier (BBB) 4, 11–12, 35, 51–52, 67–68, 75, 82, 171, 755–58, 772–74, 776–78, 780–82, 784–88, 799–801, 803–7
brain cancer cells 503, 523, 975
brain capillary endothelial cells 616, 772, 786, 806
brain capillary endothelial cells (BCEC) 616, 772, 786, 788, 806
brain tissues 757, 771–74, 777, 779, 786, 799, 950
brain tumors 56, 77, 79, 82, 108, 120, 334, 755, 778, 780–82, 785, 804

breast cancer 60, 135, 157, 285, 372, 377, 392, 397, 416, 421, 443, 445–46, 542–43, 567–69, 589–90
  metastatic 96, 241, 372–73, 416, 443–44, 568, 590, 667, 678

cancer, metastatic 22–23, 715
cancer cell viability 118, 459, 661, 671, 792
cancer cells
  breast 175, 350, 370, 438–39, 446, 471, 536, 562, 591, 976, 980
  growth of 361, 385, 485
  human 175, 477, 498, 549
cancer nanotechnology 81–83, 100, 129, 153, 159, 170, 195, 211, 232, 240, 245, 370, 392, 493, 542
cancerous cells 12, 26, 49, 109, 596, 655, 681, 735
cardiovascular diseases 29, 140, 815, 819
cellular uptake efficiency 8, 10, 168, 235, 363, 369, 388–89, 436–37, 488, 535, 708–9, 746–48, 760–61, 767–70, 777–78
cellular uptake of polymeric nanoparticles 17, 101, 128, 135, 154, 177, 193, 212, 229, 243, 260, 373, 417, 445, 716
chemical emulsifiers, traditional 253, 309–10, 376
chemotherapeutic drugs 26, 55, 590, 843, 858
chemotherapeutic engineering 4–9, 11–12, 14–15, 24–25, 27–28, 45, 50–51, 83, 97–98, 120–21, 129, 140–41, 151, 232, 656, 682, 736
chemotherapy, controlled 141, 151, 441
chitosan nanoparticles 34, 61–62, 67, 70, 76–77, 125
cholesterol 6, 46, 48–49, 111, 145, 192, 232, 287, 290–93, 297–300, 302, 471
CMC *see* critical micelle concentration
conjugated herceptin 407–9, 414
conjugation, polymer–drug 597, 618, 623, 625, 640–42
controlled drug delivery 47, 74, 76, 80, 123, 282, 335, 393, 497, 807, 946
copolymer blend nanoparticles 357, 407
copolymer nanoparticles 166, 953–54, 963
copolymer technology for advanced nanomedicine 339–44, 346
coumarin-6 88–90, 116, 133, 142, 146–47, 161, 168–69, 233, 351–52, 354, 362–65, 378–80, 386–88, 398–99, 402, 410–12, 423, 426–27, 434–36, 442, 478–79, 482, 486–88, 503–4, 509–11, 513, 570, 572–73, 578–79, 580–83, 701, 703, 708, 717–19, 721, 723–27, 737, 739, 757–74, 777–79
critical micelle concentration 276, 481, 759, 842, 849, 873, 939
critical micelle concentration (CMC) 276, 476, 481, 484, 492, 494, 759, 842–43, 849, 873, 939, 944
cytoplasm 42, 169, 364–66, 387–88, 396, 411–12, 434–35, 471–72, 486–87, 610, 730, 768, 828–29, 834–36, 878–79
cytoplasmic delivery 471–72, 474

DDD *see* drug delivery devices
DDS *see* drug delivery systems
dendrimers 7, 339, 475, 548, 812, 913
differential scanning calorimetry (DSC) 39, 86–87, 114, 180, 182, 185–86, 219, 223, 280–82, 288, 303, 657, 660, 701–2, 737
dipalmitoyl phosphatidylcholine 35–36, 38–39, 42–43, 80, 118, 145, 287, 290–94, 297–300, 303, 309–10, 312–13, 315–28, 330, 696
diseased cells 7, 15, 83, 205, 341, 347–48, 419, 468, 472, 821, 913, 964
DLE *see* drug loading efficiency
DNA-chitosan nanoparticles 34, 71, 75

docetaxel 16–17, 341–43, 366–73, 390–91, 397–99, 419–23, 440–42, 444–46, 477–80, 489–92, 522–26, 537–41, 655–60, 775–77, 788–90
  targeted delivery of 343, 350, 370, 414, 523
docetaxel-loaded nanoparticles 350, 359–60, 371, 377, 380–81, 383, 422–23, 427, 429–30, 433, 438, 657, 660–61, 666
docetaxel-loaded PLGA nanoparticles 658–59, 661–63, 667–68, 759–60, 763, 765–66, 778
docetaxel-loaded $TPGS_{2k}$ micelles 483–84
double emulsion 86, 914, 929, 946, 953, 955, 962
doxorubicin 15, 17, 61–62, 67, 124–25, 283–84, 342, 345, 393, 619–21, 624–26, 645, 756, 861, 973
DPPC *see* dipalmitoyl phosphatidylcholine
drug carriers 51, 65, 73, 283, 393, 428, 468, 476, 569, 590, 657, 678, 736, 750, 838
drug delivery, protein 963
drug delivery devices (DDD) 27, 40, 45, 50, 55, 77, 100, 114, 120–21, 123, 226, 287, 347, 425, 571
drug delivery systems (DDS) 6, 47, 54, 60, 65, 68–69, 76, 103, 123, 286, 348–49, 396, 475–76, 492–93, 940–41
drug delivery systems, novel 47, 69, 123
drug diffusion 25, 54, 107, 113, 258, 264, 301, 429–30, 578, 667, 689
drug encapsulation 43, 131, 181, 192, 227, 249, 526, 529, 704, 740, 801, 976
drug-loaded nanoparticles 35, 37–38, 42, 114–18, 145–46, 164–65, 202, 220, 350–51, 379–80, 419, 452–53, 663–65, 683–84, 744
drug-loaded PLA-TPGS nanoparticles 166, 248–49, 255, 790
drug loading 53, 112, 115–16, 131, 158, 163–66, 175, 253–56, 274–75, 469–70, 688, 704–5, 945, 951, 953–55
drug loading efficiency (DLE) 164–65, 254, 946, 955
drug release, controlled 149, 216, 225, 380, 481, 567, 756
drug release kinetics 32, 35, 40, 48, 54, 87, 110, 112, 115, 119, 235, 237, 254, 393, 572
drug release mechanisms 107, 113, 258
drug resistance 4, 26, 30, 66, 82, 106, 108–9, 140, 174, 396, 596, 625, 942
DSC *see* differential scanning calorimetry

EGFR endocytosis 473
emulsifier lipid 329–30, 332
emulsifier molecules 37, 114, 236
encapsulation efficiency 40, 163–65, 199, 253–54, 287–90, 319–22, 329–30, 383, 428–29, 456, 483–84, 664–65, 760, 764–66, 953–55
enhanced cellular uptake 414, 462–63, 597, 945, 958, 975, 977

FBS *see* fetal bovine serum
FESEM *see* field emission scanning electron microscopy
fetal bovine serum (FBS) 182, 233–34, 351, 378, 398, 422, 426, 449, 478, 499, 523, 550, 570, 572, 684–85
field emission scanning electron microscopy (FESEM) 8–9, 86, 160, 196, 199, 218, 248, 379, 501, 553, 659, 701–2, 759, 789, 892
fluorescence resonance energy transfer (FRET) 542, 548, 890
fluorescent markers 116, 142, 580, 717–19, 722, 757, 763, 777
fluorescent nanoparticles 89, 117, 133, 169, 365, 708, 718, 737, 745, 816, 840, 906
fluorescent polystyrene nanoparticles 717, 724, 730

folate-decorated nanoparticles 506–7, 513, 534–35, 539, 562
folate decoration 503, 511, 513, 523, 530, 532–39, 549, 553–58, 560–62
folate overexpression 380, 481
folate receptors 388, 394, 462–64, 477, 486, 494–95, 498, 513–16, 522–23, 543–44, 548–50, 558, 561–62, 564–65, 619–21
  over-expression of 550, 558, 561–62
folic acid 16–17, 96, 341, 345, 349–50, 371, 377–78, 384–86, 388, 478–80, 483–89, 498, 548–51, 595–96, 618
Fourier transform infra-red spectroscopy (FTIR) 38, 53, 86, 114, 246–47, 597, 600, 604, 617, 871, 890, 893, 900
FRET *see* fluorescence resonance energy transfer
FTIR *see* Fourier transform infra-red spectroscopy

gel permeation chromatography (GPC) 196–97, 201, 246–47, 252, 500, 505, 625–26, 630, 632, 658, 663, 866, 870, 895, 952
gelatin 32, 111, 287, 290–93, 297–300, 302, 309, 700, 846
gelatin nanoparticles 59–60, 69
glioma cells 143, 453, 499, 509, 625, 627, 636, 756, 758, 775–76, 781, 796–98, 801–2, 940, 942
glutaric acid 422, 424, 449, 451, 499–500, 523–25, 550, 967
GPC *see* gel permeation chromatography

Hank's balanced salt solution (HBSS) 161, 233, 570, 661, 701, 703, 717, 719–20, 739
HBSS *see* Hank's balanced salt solution
herceptin 343, 348–52, 359–60, 364, 366, 368–70, 372–73, 397–98, 400–1, 403–7, 409–10, 413–14, 467–72, 568, 589–90
high performance liquid chromatography (HPLC) 40, 87, 114–15, 142–43, 181–83, 233–34, 265–66, 282, 287, 310–12, 353, 379, 683–87, 737–38, 789–90
high performance magnetic nanoparticles 17, 649–54
HPLC *see* high performance liquid chromatography
hydrophilic drugs 6, 8, 45, 48, 85–86, 196, 216, 340, 498
hydrophobic drugs 6, 45, 86, 330, 376, 386, 397, 485

IC_{50} 9, 92, 130, 148, 197, 200, 208, 210–11, 342, 366–68, 391, 414, 437, 460, 489, 491, 538–41, 574, 586–88, 611–12, 617, 634–35, 637, 641–42, 662, 671, 673, 676, 710, 757, 776–77, 779, 793, 801, 803, 942–43, 945–46, 950, 954, 958, 967–69, 971
intestinal cells 50, 682, 716, 736, 744–45, 756
intestinal epithelial cells 42, 50, 117, 694, 716
iron oxide 17, 813–14, 816–17, 819–24, 826–28, 830–32, 836–52, 854–61, 863–67, 871–72, 874, 876–78, 880–85, 911–34, 953–54
iron oxide-loaded micelles 849, 851–52, 854–56, 858
iron oxide-loaded NPs 914, 917, 929–31
iron oxide-loaded PLA-TPGS nanoparticles 826, 867, 872, 874, 876
iron oxide-loaded PLGA-mPEG nanoparticles 914–17, 919–24, 927, 930
iron oxide-loaded TPGS micelles 848, 850, 853, 855–56, 944
iron oxide nanoparticles 654, 859, 861, 866, 883, 885

ligand conjugation 342, 344, 349, 357, 359, 361, 364, 378, 391, 396–97, 407, 778, 913
ligand molecules 350, 357, 396
lipid bilayers 6, 45–46, 376
lipid monolayers 52–53, 62–64, 80, 336, 386, 947
liposomes
  coated 946, 975
  freeze-dried 48–49
listeriolysin O (LLO) 471–72
liver 4, 26–27, 170–71, 470, 614–16, 638–40, 770–72, 787, 799–800, 832–33, 855, 857–58, 864, 880–83, 965
LLO *see* listeriolysin O
LLO liposomes 472

magnetic micelles 843–47
magnetic nanoparticles 650–51, 654, 816, 860, 884
magnetic resonance imaging (MRI) 17, 811–12, 816–17, 820, 826, 833, 836–43, 847, 857–61, 863–64, 881–83, 911–12, 914, 933, 963–64
maximum tolerance dose (MTD) 390–91, 468, 613, 638
MBC *see* metastatic breast cancer
MCF7 cells 364–66, 380–81, 387–88, 411–12, 481–82
MDCK cells 760–61, 767–68, 777, 779, 950
MDR *see* multi-drug resistance
metastatic breast cancer (MBC) 96, 241, 348, 372–73, 397, 416, 443–44, 568, 589–90, 667, 678
micelles 5–6, 16, 119–20, 415–16, 469–71, 475–80, 482–86, 488, 490–94, 812–13, 842, 847–61, 872–73, 940–41, 944–45
  conjugated 470, 483, 486, 488–89
molecular biomaterials 7, 939–40, 942, 944, 946, 948, 950, 952, 954, 956, 958, 960, 962, 966, 968, 970
mononuclear phagocytosis system (MPS) 171, 799–800, 820
MPS *see* mononuclear phagocytosis system
MRI *see* magnetic resonance imaging
MTD *see* maximum tolerance dose
multi-drug resistance (MDR) 26, 30, 49, 109, 158, 303, 371, 460, 595, 618, 624, 643–44, 803, 854–55, 940
multi-functional nanoparticles 17, 95, 98–99, 343, 519, 843, 978
multi-modal imaging 11, 14, 809, 811–16, 821, 832, 964, 980
multi-modal therapy 22, 652–53
multi-modal tumor imaging 17, 346, 817, 819–20, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 980

N-hydroxysuccinimide (NHS) 351, 398, 400, 422–24, 449, 451–52, 454, 471, 478–79, 499–500, 523–25, 550–51, 598–99, 604–5, 625
nanocarriers 6–7, 14, 340, 342, 344, 348, 370, 396, 398, 415, 470, 474, 787–88, 812, 815
nanoconjugation 472–74
nanoimmunotherapy 15
nanomedicine 83, 129, 191, 340, 342–43, 421, 521, 653, 940–41
nanoparticle characterization 35, 86–87, 111, 142, 160, 233, 702, 718
nanoparticle drug delivery systems 349
nanoparticle technology for chemotherapy 29, 31, 33, 35, 37, 39, 41, 43
nanoparticles
  cellular uptake of 11–12, 36, 88, 246, 717, 723, 727
  coated 51, 117, 393, 949, 954
  coumarin-6-loaded 142, 146–47, 435, 768, 774
  freeze-dried 274, 401, 738
  inorganic 14, 84, 97, 131, 151, 170, 342, 475
  internalized 117, 720, 728, 730

non-degradable 14, 151, 170
paclitaxel-loaded MPEG-PLA 184, 186–87
nanoparticles of biodegradable copolymers 343, 597, 889
nanoparticles of biodegradable polymers 6, 13–15, 29–30, 81–84, 92, 94–102, 104–8, 119–21, 135, 140, 151–52, 192–93, 588, 675–77, 730–31
nanoparticles of PLA-TPGS copolymers 94, 130, 837
nanoprecipitation 101, 124, 180–81, 184, 191, 216–17, 219–20, 225, 350–51, 864–65, 867, 873–77, 882, 947, 953
nanospheres 36, 61, 72, 102, 123–24, 128, 153, 193, 226, 308–9, 311, 313–14, 316–33, 335, 806
emulsified 318, 325, 328–29
fabricated 321, 332
nanotechnology for multimodal imaging 811–16
nanothermotherapy 15, 17, 649–54, 842–43
new-concept chemotherapy 81–86, 88, 90, 92, 94, 96–100, 102, 104–10, 112, 114, 116, 151–52, 588, 677, 973
NHS *see* *N*-Hydroxysuccinimide
non-targeting nanoparticles (NTN) 788, 790, 796
NTN *see* non-targeting nanoparticles

optical imaging 811–12, 816
oral chemotherapy 4–5, 11–12, 16, 49–51, 108–10, 119–20, 232–33, 655–56, 676–77, 681, 695, 699, 711, 715–17, 735–36
oral drug delivery 69, 74, 207, 448, 476, 682, 770

paclitaxel
biodistribution of 162, 170, 694
clinical administration of 17, 63, 100–1, 107, 124, 135, 152, 154, 192, 211, 226, 242, 265, 312, 465
clinical application of 24, 106, 308
controlled release of 16, 101, 123–24, 152–53, 242–43, 259, 306–8, 332, 416–17, 444–45, 591, 619, 713, 732, 783
encapsulation efficiency of 235, 267, 289–90
extraction of 24, 107, 308
formulation of 86, 117, 177, 216, 231–32, 234, 236, 238, 240, 242, 342, 445, 465, 516, 691
nanoparticle formulation of 86, 92, 150–51, 476, 700
oral 5, 71, 126, 677, 683, 696
oral bioavailability of 5, 683, 691, 701, 735
oral delivery of 42, 50, 232, 656, 683, 736–37
targeted delivery of 437, 597
paclitaxel-loaded nanoparticles 41, 93, 115, 143, 145, 149, 160, 188, 217–18, 225, 246, 253–56, 259, 500–1, 503
paclitaxel-loaded PLA-TPGS nanoparticles 84, 93, 163, 166–67, 174–75, 248, 252, 254–59, 341
PBS *see* phosphate buffered saline
PEG *see* polyethylene glycol
PEG copolymers 341
PEGylation 5, 85, 341, 941
peptide nucleic acid (PNA) 60, 127
PGA *see* poly(L-glutamic acid)
pharmaceutical nanotechnology 232
pharmacokinetics 4, 25, 54, 82, 106, 108–9, 120–21, 140, 159, 161, 169, 172, 175, 191, 642
phosphate buffered saline (PBS) 200, 353–54, 402, 426–27, 453, 503–4, 528–29, 601–4, 627, 660–62, 760–63, 823–26, 844–46, 868–69, 893–95
physiological drug barrier 4, 82, 96–97, 99, 108, 120–21, 140, 419
PLA *see* poly(D,L-lactic acid)
PLA nanoparticles 44, 119, 278

PLA-PEG nanoparticles 44, 119, 171
PLA-TPGS copolymers 8, 130, 159–60, 198, 201, 246–47, 249–55, 498–99, 505, 549–50, 663–65, 822–23, 870–71, 895, 952–53
PLA-TPGS nanoparticles 93, 157–60, 162, 164–66, 168–76, 178, 205, 254, 258, 341–44, 397, 416, 704–5, 828, 890
PLGA microspheres 49, 290–91, 293, 298, 300, 302
PLGA/MMT nanoparticles 587, 736–39, 744, 748
PLGA nanospheres 38, 316–17, 321, 326–27
PNA *see* peptide nucleic acid
poly(D,L-lactic acid) (PLA) 8, 40–41, 61, 85, 93, 195–96, 215–17, 219–21, 224–25, 278–80, 309–10, 663, 822, 870, 951–52
poly(L-glutamic acid) (PGA) 85, 340, 596, 624, 941, 952
polyethylene glycol (PEG) 5–6, 46, 180, 216, 228, 340–41, 348–49, 377–78, 476–78, 521, 542, 624, 812–13, 939, 941
polymer-core nanoparticles 376, 382
polymer matrix swelling 107, 258
polymeric matrix materials 245, 254–55, 513, 929
polymeric microspheres 47–48, 141, 158, 294, 783, 946, 976, 978
polymeric nanospheres 16, 72, 101, 124, 135, 153, 177, 193, 211, 243, 259, 284, 310, 312, 619
polymeric particles, biodegradable 263, 913
polymeric prodrugs 596, 617–18
polysorbate 33, 57, 64, 67, 125, 180, 421, 477, 781–83, 788
polystyrene nanoparticles 726, 729–30
polyvinyl alcohol 35–36, 116, 145, 159, 197, 232, 265, 282, 287, 303, 309–10, 376, 569–70, 764–69, 774–76
post-conjugation strategy 350, 396–97, 407
pre-conjugation strategy 349–50, 396–97, 407
preformed polymers 31, 86, 864
prodrugs 5, 55, 339, 341, 593, 595–97, 616, 624–25, 630, 639, 641–42, 682, 941–43, 968
propidium iodide 122, 142, 146, 152, 161, 175–76, 364–65, 387–88, 411–12, 427–28, 486–88, 571, 573, 670, 768
pyridine 398, 449–52, 454, 499–500, 523, 550–51, 967

QDs
  see quantum dots
  cytotoxicity of 539, 548, 562, 904
QDs encapsulation efficiency 527, 534, 549, 553–54, 556, 828, 894, 902, 905
quantum dots (QDs) 16–17, 522–27, 531–36, 538–39, 543–44, 547–51, 553–54, 556–60, 562–66, 813–14, 820–24, 826–39, 887–95, 899–908, 963–66

receptor-mediated endocytosis (RME) 348, 364, 388, 411, 415, 477, 486, 488, 549, 560, 596, 772–73, 798, 805
RME *see* receptor-mediated endocytosis

scanning electron microscopy (SEM) 35, 86, 142, 216, 233–34, 267, 281–82, 288, 301–3, 309, 311, 318, 329, 717–18, 737–38
SEM *see* scanning electron microscopy
silica nanoparticles 813–14, 817, 906
single emulsion 84, 86, 141, 159, 233, 266, 276, 281, 303, 309–10, 312, 381, 441, 499–500, 513, 531, 683–84, 687, 717, 757–58, 865, 867, 871–73, 882, 891, 940, 953–54, 963–64
SLN *see* solid lipid nanoparticles

small-molecule drug chemotherapy 179, 191, 392, 885
solid lipid nanoparticles (SLN) 7, 34, 44, 59, 65, 72, 76, 80, 102, 119, 123, 127, 392, 781, 976
solid lipid nanoparticles, long-circulating 44, 59, 102, 119, 127
solid tumors 23, 26–27, 55, 58, 60, 62, 66–67, 78, 103, 126–27, 228, 232, 497, 514, 563
spleen 46, 61, 162, 170–71, 174, 470, 604, 614–16, 629, 638–40, 757, 762, 770–72, 777, 799–800
stannous octoate 197, 247, 249, 398–99, 422, 424, 449, 499, 550, 658, 866, 891, 951
superparamagnetic iron oxides 17, 817, 839, 863, 911–12, 914, 916, 918, 920, 922, 924, 926, 928, 930, 932

targeted drug delivery, quantitative control of 364, 367
TEM *see* transmission electron microscopy
TGA *see* thermal gravimetric analysis
thermal gravimetric analysis (TGA) 571, 577–78, 657, 660, 664, 737–38, 741, 844, 849–50, 952
tocopheryl polyethylene glycol succinate (TPGS) 40–43, 111–18, 195–98, 200–8, 235–38, 249–60, 268–70, 272–82, 397–400, 475–78, 595–98, 640–42, 764–72, 939–56, 972–80
TPGS *see* tocopheryl polyethylene glycol succinate
TPGS-coated nanoparticles 117, 723, 727–28
TPGS-coated PLGA nanoparticles 90–91, 168, 238, 717, 723, 730
TPGS-coated PLGA NPs 709, 950
TPGS-emulsified nanoparticles 130, 135, 145, 940, 947, 949
transmission electron microscopy (TEM) 89, 112, 382, 553, 717, 720–21, 729–30, 844, 847, 855–56, 865, 892, 898, 914–15, 930
trastuzumab 96, 103, 135, 372–73, 416, 420–21, 423–24, 428–31, 437, 442–44, 568–70, 574–76, 582–84, 586–91, 970
trastuzumab conjugation 420, 423, 427, 434, 437, 439
trastuzumab decoration 569, 573–75, 578, 580, 583, 586–88
tumors, primary 22, 56

vibrating sample magnetometer (VSM) 844, 851, 868, 914
vitamin E TPGS 32, 35, 38, 40–43, 50, 87–89, 91, 112–17, 139–51, 196, 231–40, 245–47, 249, 251–52, 263–65, 268–70, 274–76, 278–79, 281–82, 398, 421, 447–48, 475–76, 497–99, 522–23, 549–50, 562–63, 597, 624, 656, 658, 681–82, 684, 695, 699–700, 716–18, 721–24, 727–30, 759, 788, 812, 866, 887, 890–91, 939
VSM *see* vibrating sample magnetometer

water-soluble polymers 348, 493, 618, 643, 973